If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

 

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNovacyt Regulatory News (NCYT)

Share Price Information for Novacyt (NCYT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 64.00
Bid: 63.40
Ask: 66.00
Change: -1.50 (-2.27%)
Spread: 2.60 (4.101%)
Open: 64.00
High: 64.00
Low: 64.00
Prev. Close: 66.20
NCYT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Cancellation of trading of Yourgene Shares

11 Sep 2023 07:55

RNS Number : 9939L
Novacyt S.A.
11 September 2023
 

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

 

De-listing and cancellation of trading of Yourgene Shares

 

Paris, France and Eastleigh, UK - 11 September 2023 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, notes today's announcement by Yourgene Health plc ("Yourgene"), in relation to the recommended cash offer made by Novacyt UK Holdings Limited ("Novacyt UK"), a wholly-owned subsidiary of Novacyt, for the entire issued and to be issued share capital of Yourgene announced on 3 July 2023 (the "Acquisition"), which is to be effected by means of a Court-sanctioned scheme of arrangement under Part 26 of the Companies Act 2006 (the "Scheme").

 

Further to the announcement made by Yourgene on 8 September 2023 that the Scheme has now become Effective in accordance with its terms, Yourgene has today announced that, following an application to the London Stock Exchange, the admission to trading on AIM of Yourgene Shares has been cancelled with effect from 7.00 a.m. today, 11 September 2023.

 

Yourgene's full announcement can be found here: https://polaris.brighterir.com/public/yourgenehealth/news/rns/story/wkjon2r

 

Contacts

 

Novacyt SA

+44 (0)23 8074 8830

James Wakefield, Non-Executive Chairman

James McCarthy, Acting Chief Executive Officer

Numis (Financial Adviser and Joint Broker to Novacyt and Financial Adviser to Novacyt UK)

+44 (0)20 7260 1000

Freddie Barnfield / Stuart Ord / Duncan Monteith / Jack McLaren

SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker to Novacyt)

+44 (0)20 3470 0470

 

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

 +33 (1) 42 22 10 10 r.durgetto@allegrafinance.com / y.petit@allegrafinance.com

Walbrook PR (Financial PR & IR)

Stephanie Cuthbert / Anna Dunphy / Phillip Marriage

+44 (0)20 7933 8780

novacyt@walbrookpr.com

 

About Novacyt Group

Novacyt is an international diagnostics business delivering a broad portfolio of in vitro and molecular diagnostic tests for a wide range of infectious diseases, enabling faster, more accurate, accessible testing to improve healthcare outcomes. The Company provides customers with a seamless sample-to-result workflow using its integrated and scalable instrumentation/solutions. The Company specialises in the design, manufacture, and supply of real-time PCR kits, reagents and a full range of laboratory and qPCR instrumentation for molecular biology research and clinical use. Novacyt offers one of the world's most varied and comprehensive range of qPCR assays, covering human, veterinary, biodefence, environmental, agriculture and food testing.

 

Novacyt is headquartered in Vélizy in France with offices in Stokesley and Eastleigh, UK, and is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

 

For more information, please refer to the website: www.novacyt.com

 

About Yourgene Health

Yourgene Health is an international integrated technologies and services business, enabling the delivery of genomic medicine. The Group works in partnership with global leaders in DNA technology to advance diagnostic science.

 

Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic and screening solutions, for reproductive health and precision medicine. The Group's portfolio of in vitro diagnostic products includes non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests and DPYD genotyping assays.

 

Building on our expertise in genomic technology, Yourgene's Ranger® Technology offers next generation size selection with a range of sample preparation platforms for dynamic target enrichment. Ranger® Technology can be utilised to improve workflows and performance in multiple applications including NIPT, oncology, infectious disease testing and gene synthesis.

 

Yourgene Genomic Services offers a clinical service from UK and Taiwan focusing on precision medicine and reproductive health, including NIPT.

 

Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN".

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFIFLRADILLIV
Date   Source Headline
12th Mar 202111:00 amRNSHoldings in Company
1st Mar 20212:30 pmRNSLiquidity Agreement and Total Voting Rights
24th Feb 20216:30 pmRNSCorrection: Research and Development Update
24th Feb 20217:00 amRNSResearch and Development Update
2nd Feb 20217:00 amRNSLaunch of PCR assay portfolio
1st Feb 202112:30 pmRNSTotal Voting Rights
29th Jan 20217:00 amRNSFull Year 2020 Trading Update
26th Jan 20215:30 pmRNSHolding(s) in Company
13th Jan 202112:30 pmRNSHoldings in Company
5th Jan 20217:00 amRNSExecutive Management and Proposed Board Changes
4th Jan 20212:15 pmRNSLiquidity Agreement and Total Voting Rights
21st Dec 20207:00 amRNSNew COVID-19 variant
14th Dec 20207:00 amRNSTests for new strains of COVID-19 and avian flu
2nd Dec 20201:15 pmRNSHolding(s) in Company
1st Dec 20202:15 pmRNSLiquidity Agreement and Total Voting Rights
18th Nov 20206:20 pmRNSDirector/PDMR Shareholding
16th Nov 20207:00 amRNSR&D Update
13th Nov 20206:05 pmRNSDirector/PDMR Shareholding
13th Nov 20207:00 amRNSDirector/PDMR Shareholding
12th Nov 20207:00 amRNSDirector/PDMR Shareholding
11th Nov 202011:05 amRNSDirector/PDMR Shareholding
2nd Nov 20201:00 pmRNSLiquidity Agreement and Total Voting Rights
28th Oct 20204:41 pmRNSSecond Price Monitoring Extn
28th Oct 20204:35 pmRNSPrice Monitoring Extension
28th Oct 20202:06 pmRNSSecond Price Monitoring Extn
28th Oct 20202:00 pmRNSPrice Monitoring Extension
15th Oct 202011:30 amRNSAcquisition of IT-IS International Ltd
2nd Oct 20201:30 pmRNSLiquidity Agreement and Total Voting Rights
29th Sep 20205:00 pmRNSResult of AGM
29th Sep 202011:05 amRNSSecond Price Monitoring Extn
29th Sep 202011:00 amRNSPrice Monitoring Extension
29th Sep 20209:05 amRNSSecond Price Monitoring Extn
29th Sep 20209:00 amRNSPrice Monitoring Extension
29th Sep 20207:00 amRNSLaunch of COVID-19 antibody test
29th Sep 20207:00 amRNSNew UK DHSC Contract
28th Sep 20203:00 pmRNSAppointment of ODDO BHF
21st Sep 202011:05 amRNSSecond Price Monitoring Extn
21st Sep 202011:00 amRNSPrice Monitoring Extension
18th Sep 20207:00 amRNSAGM Voting
17th Sep 20207:00 amRNSHalf year 2020 results
16th Sep 20207:00 amRNSAppointment of Joint Broker
4th Sep 20207:00 amRNSLaunch of two gene COVID-19 test
1st Sep 20202:00 pmRNSLiquidity Agreement and Total Voting Rights
27th Aug 20207:00 amRNSLaunch of respiratory test panel
19th Aug 20201:15 pmRNSNotice of AGM
3rd Aug 20201:30 pmRNSLiquidity Agreement and Total Voting Rights
27th Jul 20207:00 amRNSR&D Update
22nd Jul 20204:41 pmRNSSecond Price Monitoring Extn
22nd Jul 20204:36 pmRNSPrice Monitoring Extension
22nd Jul 20203:30 pmRNS2000 patient trial using Novacyt's testing system

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.